A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects

Trial Profile

A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Peginterferon lambda-1a (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational
  • Acronyms BASIS
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 20 Nov 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
    • 12 Jun 2014 Planned number of patients changed from 45 to 40 as reported by ClinicalTrials.gov record.
    • 07 May 2014 Planned number of patients changed from 300 to 45 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top